SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $723,285 | -21.1% | 49,813 | +13.8% | 0.00% | – |
| Q2 2023 | $916,231 | -24.1% | 43,776 | -23.4% | 0.00% | -100.0% |
| Q1 2023 | $1,206,882 | +8.8% | 57,144 | +31.1% | 0.00% | 0.0% |
| Q4 2022 | $1,109,238 | +71.7% | 43,585 | +62.1% | 0.00% | – |
| Q3 2022 | $646,000 | +3.4% | 26,880 | -17.2% | 0.00% | – |
| Q2 2022 | $625,000 | +15.7% | 32,464 | +4.5% | 0.00% | – |
| Q1 2022 | $540,000 | -18.1% | 31,073 | +3.3% | 0.00% | – |
| Q4 2021 | $659,000 | +20.3% | 30,083 | +4.8% | 0.00% | – |
| Q3 2021 | $548,000 | +4.8% | 28,717 | -5.7% | 0.00% | – |
| Q2 2021 | $523,000 | +4.4% | 30,453 | +35.8% | 0.00% | – |
| Q1 2021 | $501,000 | +3.7% | 22,418 | +3.2% | 0.00% | – |
| Q4 2020 | $483,000 | +121.6% | 21,724 | +46.9% | 0.00% | – |
| Q3 2020 | $218,000 | -48.2% | 14,791 | -47.9% | 0.00% | – |
| Q2 2020 | $421,000 | +367.8% | 28,378 | +247.0% | 0.00% | – |
| Q1 2020 | $90,000 | +34.3% | 8,178 | +5.5% | 0.00% | – |
| Q4 2019 | $67,000 | +45.7% | 7,754 | +21.6% | 0.00% | – |
| Q3 2019 | $46,000 | -69.3% | 6,379 | -60.7% | 0.00% | – |
| Q2 2019 | $150,000 | +59.6% | 16,233 | -10.3% | 0.00% | – |
| Q1 2019 | $94,000 | +16.0% | 18,097 | -1.9% | 0.00% | – |
| Q4 2018 | $81,000 | -94.1% | 18,452 | -89.1% | 0.00% | – |
| Q3 2018 | $1,367,000 | +192.7% | 169,360 | +154.0% | 0.00% | – |
| Q2 2018 | $467,000 | -26.1% | 66,676 | +49.8% | 0.00% | – |
| Q1 2018 | $632,000 | +71.3% | 44,503 | +5.3% | 0.00% | – |
| Q4 2017 | $369,000 | +27.2% | 42,275 | +68.7% | 0.00% | – |
| Q3 2017 | $290,000 | -18.1% | 25,062 | -1.6% | 0.00% | – |
| Q2 2017 | $354,000 | -21.2% | 25,468 | -22.5% | 0.00% | – |
| Q1 2017 | $449,000 | +2263.2% | 32,841 | +1101.6% | 0.00% | – |
| Q4 2016 | $19,000 | +72.7% | 2,733 | +251.7% | 0.00% | – |
| Q3 2016 | $11,000 | -79.6% | 777 | -86.1% | 0.00% | – |
| Q2 2016 | $54,000 | +38.5% | 5,573 | +86.5% | 0.00% | – |
| Q1 2016 | $39,000 | – | 2,989 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |